news – Page 54 – pharmaceutical daily

November 10, 2025 Off

George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025

London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs…

November 10, 2025 Off

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD – The Liver Meeting® 2025

By GlobeNewswire

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical…

November 10, 2025 Off

Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025

By GlobeNewswire

BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by…

November 9, 2025 Off

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

By GlobeNewswire

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of…

November 9, 2025 Off

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

By GlobeNewswire

Oral presentation highlights sotagliflozin’s unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of lifeTHE…

November 9, 2025 Off

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

By GlobeNewswire

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a…

November 9, 2025 Off

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

By GlobeNewswire

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been…

November 9, 2025 Off

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

By GlobeNewswire

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and…

November 9, 2025 Off

Judo Bio’s Megalin-STRIKERs Achieve First Demonstration of Functional Pharmacodynamic Effects from Kidney Selective Gene Silencing in Non-Human Primates

By GlobeNewswire

Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels…

November 9, 2025 Off

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

By GlobeNewswire

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq:…